Alpha -Tocopherol Acetate D- Calcium Carbonate Cal

證據等級: L5

預測適應症: 0 個

Multivitamin-Mineral Complex (15-Component): Evaluation Not Possible — Insufficient Data

One-Sentence Summary

This entry represents a 15-component vitamin and mineral combination (including Vitamins B1, B2, B3, B6, B9, B12, C, D3, E, plus calcium, iron, zinc, iodine, and choline), consistent with a comprehensive prenatal or therapeutic multivitamin formula. The TxGNN model returned no predicted indications for this combination, and the compound is currently not registered in Taiwan. As a result, a standard drug repurposing evaluation cannot be completed with the available data.

Quick Overview

Item	Content
Original Indication	None recorded
Predicted New Indication	None (TxGNN returned no predictions)
TxGNN Prediction Score	N/A
Evidence Level	L5 — Model prediction only; no actual predictions generated
US Market Status	Not marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

No TxGNN repurposing prediction was generated for this entry. This is most likely because the query submitted to the pipeline was a multi-component mixture string rather than a single active pharmaceutical ingredient (API), which the TxGNN knowledge graph cannot process as a unified entity.

The 15 components — spanning water-soluble vitamins (B-complex, vitamin C), fat-soluble vitamins (D3, E), macrominerals (calcium), trace minerals (iron, zinc, iodine), and a phospholipid precursor (choline) — are each individually well-characterised in DrugBank and the TxGNN knowledge graph. However, the pipeline requires a single DrugBank ID as input. No DrugBank ID was resolved for this compound string, confirming the mapping failure.

To unlock a meaningful repurposing analysis, the pipeline would need to be re-run on each individual component separately, or on the most pharmacologically active constituent of interest (e.g., cholecalciferol, folic acid, or cyanocobalamin), before combining results.

Clinical Trial Evidence

Currently no related clinical trials registered for this combination as a unified entity.

Note: Individual components (e.g., folic acid for neural tube defect prevention, cholecalciferol for bone health) have extensive clinical trial records. A component-level search is recommended.

Literature Evidence

Currently no related literature available for this specific 15-component mixture as a single entity.

Safety Considerations

Please refer to the package insert for safety information.

Note: No Taiwan TFDA monograph was retrieved (market status: not registered). For individual component safety data, consult DrugBank entries for each ingredient.

Conclusion and Next Steps

Decision: Hold

Rationale: The TxGNN pipeline failed to generate any repurposing predictions because the query was submitted as a multi-component ingredient string without a resolvable DrugBank ID, making systematic evaluation impossible at this time.

To proceed, the following is needed:

Decompose the query: Re-run TxGNN predictions on each of the 15 individual active ingredients separately (D-alpha-tocopherol acetate, cholecalciferol, folic acid, cyanocobalamin, etc.)
Identify the lead compound: Determine which single component is the primary subject of the repurposing hypothesis, then generate a targeted Evidence Pack for that ingredient
Resolve DrugBank IDs: Map each ingredient to its individual DrugBank ID (e.g., folic acid → DB00158, cholecalciferol → DB00169) to enable knowledge graph traversal
Clarify clinical context: Determine whether this formulation is intended as a prenatal supplement, a therapeutic micronutrient replacement, or another clinical application — this will guide which component to prioritise
Taiwan registration check: If market entry is the goal, confirm whether individual components or the full combination requires NDA filing with TFDA
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.